These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23437092)

  • 41. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
    Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
    Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs.
    Vekeman F; Magestro M; Karner P; Duh MS; Nichols T; van Waalwijk van Doorn-Khosrovani SB; Zonnenberg BA
    J Med Econ; 2015; 18(12):1060-70. PubMed ID: 26201433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands.
    Eijkemans MJ; van der Wal W; Reijnders LJ; Roes KC; van Waalwijk van Doorn-Khosrovani SB; Pelletier C; Magestro M; Zonnenberg B
    Am J Kidney Dis; 2015 Oct; 66(4):638-45. PubMed ID: 26165440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
    Xu KF; Zhang P; Tian X; Ma A; Li X; Zhou J; Zeng N; Gui YS; Guo Z; Feng R; Zhang W; Sun W; Cai B
    Respir Med; 2013 Feb; 107(2):263-8. PubMed ID: 23127572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
    Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
    J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
    Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
    Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
    Brakemeier S; Bachmann F; Budde K
    Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
    Lam HC; Siroky BJ; Henske EP
    Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex.
    Al-Saleem T; Wessner LL; Scheithauer BW; Patterson K; Roach ES; Dreyer SJ; Fujikawa K; Bjornsson J; Bernstein J; Henske EP
    Cancer; 1998 Nov; 83(10):2208-16. PubMed ID: 9827727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.
    Janssens P; Van Hoeve K; De Waele L; De Rechter S; Claes KJ; Van de Perre E; Wissing KM; Bammens B; Jansen A; Mekahli D
    Pediatr Nephrol; 2018 Nov; 33(11):2085-2093. PubMed ID: 29987458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
    Woodrum C; Nobil A; Dabora SL
    J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.
    Swallow E; King S; Song J; Peeples M; Signorovitch JE; Liu Z; Prestifilippo J; Frost M; Kohrman M; Korf B; Krueger D; Sparagana S
    Urology; 2017 Jun; 104():110-114. PubMed ID: 28263820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
    Overwater IE; Rietman AB; Bindels-de Heus K; Looman CW; Rizopoulos D; Sibindi TM; Cherian PJ; Jansen FE; Moll HA; Elgersma Y; de Wit MC
    Neurology; 2016 Sep; 87(10):1011-8. PubMed ID: 27511181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New staging criteria predicting m-tor inhibitors treatment effect of renal angiomyolipoma in tuberous sclerosis complex patients.
    Wang W; Qiu D; Zhao Y; Wang Z; Wang X; Li Y; Liu Y; Liao Z; Zhang Y
    World J Urol; 2024 Sep; 42(1):532. PubMed ID: 39302433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Effectiveness of Medical Therapy and Surgical Intervention for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
    Wang Z; Zhang W; Fan Y; Zhang X
    Cancer Control; 2022; 29():10732748221140266. PubMed ID: 36471546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genotype-phenotype correlation of patients with tuberous sclerosis complex-associated renal angiomyolipoma: a descriptive study.
    Li S; Zhang Y; Wang Z; Yang Y; Gao W; Li D; Wei J
    Hum Pathol; 2018 Dec; 82():61-67. PubMed ID: 30036593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy.
    Ruiz Guerrero E; Ledo Cepero MJ; Ojeda Claro AV; Soto Delgado M; Álvarez-Ossorio Fernández JL
    Actas Urol Esp (Engl Ed); 2021 May; 45(4):264-272. PubMed ID: 33637375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
    Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.